文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

脂蛋白(a):从心血管之谜到治疗靶点的漫长之旅。

The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target.

机构信息

Robarts Research Institute, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada; Department of Physiology & Pharmacology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada.

Institute of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, Austria.

出版信息

Atherosclerosis. 2022 May;349:1-6. doi: 10.1016/j.atherosclerosis.2022.04.017.


DOI:10.1016/j.atherosclerosis.2022.04.017
PMID:35606069
Abstract

Atherosclerosis, as the official journal of the European Atherosclerosis Society (EAS), decided that it would be timely to publish a comprehensive collection of review articles on lipoprotein(a). Spanning the last decade or two, this lipoprotein has become a further target in the fight against atherosclerotic cardiovascular disease. In that time, detailed knowledge about lipoprotein(a) has grown tremendously. Therefore, we decided not to have just one review article covering all aspects of lipoprotein(a), but rather to invite established experts in the field to write in-depth review articles on various aspects of lipoprotein(a). Collectively, these articles cover epidemiology, genetics, non-genetic influences, the influence of ethnicity, basic scientific investigations on the pathogenicity of lipoprotein(a), therapeutic developments to lower lipoprotein(a), and the challenging related to measurement of lipoprotein(a). The end result is a collection of 13 articles, which should be considered as the most comprehensive overview on the lipoprotein(a) field currently available. At the same time, the EAS invited the scientific community to submit original research papers in various areas of lipoprotein(a) research. This has resulted in an additional 15 articles that are part of an extended Atherosclerosis Special Issue along with the invited review articles.

摘要

动脉粥样硬化作为欧洲动脉粥样硬化学会(EAS)的官方期刊,决定适时发表一篇关于脂蛋白(a)的综述文章合集。在过去的十几年中,这种脂蛋白已成为对抗动脉粥样硬化性心血管疾病的又一目标。在这段时间里,人们对脂蛋白(a)的详细了解有了极大的增长。因此,我们决定不只有一篇综述文章涵盖脂蛋白(a)的所有方面,而是邀请该领域的知名专家撰写关于脂蛋白(a)各个方面的深入综述文章。这些文章共同涵盖了流行病学、遗传学、非遗传因素、种族影响、脂蛋白(a)致病性的基础科学研究、降低脂蛋白(a)的治疗进展,以及与脂蛋白(a)测量相关的具有挑战性的问题。最终的结果是汇集了 13 篇文章,这些文章应该被认为是目前脂蛋白(a)领域最全面的综述。与此同时,EAS 还邀请了科学界提交脂蛋白(a)研究各个领域的原始研究论文。这促成了另外 15 篇文章,它们与特邀综述文章一起作为扩展的《动脉硬化》特刊的一部分。

相似文献

[1]
The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target.

Atherosclerosis. 2022-5

[2]
Impact Factors and Prediction of Popular Topics in a Journal.

Ultraschall Med. 2016-8

[3]
Rules to be adopted for publishing a scientific paper.

Ann Ital Chir. 2016

[4]
The inaugural Qatar Critical Care Conference with its Qatar Medical Journal Special Issue - An important milestone.

Qatar Med J. 2019-11-7

[5]
Targeting Lipoprotein (a) to Understand its Impact on Atherosclerotic Cardiovascular Disease.

Curr Pharm Des. 2022

[6]
Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM.

Clin Chem Lab Med. 2020-3-26

[7]
Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.

Clin Res Cardiol Suppl. 2019-4

[8]
Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice.

Curr Atheroscler Rep. 2019-7-27

[9]
Medical journals in the Republic of Macedonia after the Second World War.

Prilozi. 2011

[10]
Oxidized phospholipids and lipoprotein(a): An update.

Eur J Clin Invest. 2022-4

引用本文的文献

[1]
2024: The year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings.

Arch Med Sci. 2025-2-22

[2]
Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels.

Arch Med Sci. 2024-1-31

[3]
Lifestyle and Lipoprotein(a) Levels: Does a Specific Counseling Make Sense?

J Clin Med. 2024-1-28

[4]
Lipoprotein(a): from Causality to Treatment.

Curr Atheroscler Rep. 2024-3

[5]
Estimating the Prevalence and Characteristics of Patients Potentially Eligible for Lipoprotein(a)-Lowering Therapies in a Real-World Setting.

Biomedicines. 2023-12-12

[6]
Stratification in Heterozygous Familial Hypercholesterolemia: Imaging, Biomarkers, and Genetic Testing.

Curr Atheroscler Rep. 2023-12

[7]
Lipoprotein(a)-60 Years Later-What Do We Know?

Cells. 2023-10-17

[8]
Assessment of Apolipoprotein(a) Isoform Size Using Phenotypic and Genotypic Methods.

Int J Mol Sci. 2023-9-9

[9]
Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?

Atheroscler Plus. 2023-9-9

[10]
Evidence and Uncertainties on Lipoprotein(a) as a Marker of Cardiovascular Health Risk in Children and Adolescents.

Biomedicines. 2023-6-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索